WallStSmart

Insmed Inc (INSM)vsPharming Group NV (PHAR)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Insmed Inc generates 61% more annual revenue ($606.42M vs $376.13M). PHAR leads profitability with a 0.8% profit margin vs -2.1%. PHAR earns a higher WallStSmart Score of 39/100 (F).

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77

PHAR

Hold

39

out of 100

Grade: F

Growth: 8.0Profit: 5.0Value: 3.0Quality: 6.3
Piotroski: 4/9Altman Z: 1.33
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for INSM.

PHARSignificantly Overvalued (-732.6%)

Margin of Safety

-732.6%

Fair Value

$1.87

Current Price

$16.23

$14.36 premium

UndervaluedFair: $1.87Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

INSM0 strengths · Avg: 0/10

No standout strengths identified

PHAR1 strengths · Avg: 10.0/10
EPS GrowthGrowth
98.1%10/10

Earnings expanding 98.1% YoY

Areas to Watch

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

PHAR4 concerns · Avg: 2.8/10
Market CapQuality
$1.11B3/10

Smaller company, higher risk/reward

Return on EquityProfitability
1.0%3/10

ROE of 1.0% — below average capital efficiency

Profit MarginProfitability
0.8%3/10

0.8% margin — thin

P/E RatioValuation
399.3x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bull Case : PHAR

The strongest argument for PHAR centers on EPS Growth. Revenue growth of 14.9% demonstrates continued momentum.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Bear Case : PHAR

The primary concerns for PHAR are Market Cap, Return on Equity, Profit Margin. A P/E of 399.3x leaves little room for execution misses. Thin 0.8% margins leave little buffer for downturns.

Key Dynamics to Monitor

INSM profiles as a turnaround stock while PHAR is a value play — different risk/reward profiles.

INSM carries more volatility with a beta of 1.17 — expect wider price swings.

PHAR is growing revenue faster at 14.9% — sustainability is the question.

PHAR generates stronger free cash flow (6M), providing more financial flexibility.

Bottom Line

INSM scores higher overall (39/100 vs 39/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Pharming Group NV

HEALTHCARE · BIOTECHNOLOGY · USA

Pharming Group NV, a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company is headquartered in Leiden, the Netherlands.

Want to dig deeper into these stocks?